<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320345</url>
  </required_header>
  <id_info>
    <org_study_id>FAME0001</org_study_id>
    <secondary_id>ACTRN12611000249954</secondary_id>
    <nct_id>NCT01320345</nct_id>
  </id_info>
  <brief_title>A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume</brief_title>
  <acronym>FAME 1 EYE</acronym>
  <official_title>The Fenofibrate And Microvascular Event Eye (FAME 1 EYE) Trial: A Randomised Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Daily Oral Fenofibrate Compared With Placebo on Macular Thickness and Volume</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Vincent's Hospital Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Prince Alfred Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential benefits of Fenofibrate in 300 adults
      with Type 1 diabetes mellitus who are at high risk of eye damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is the commonest cause of adult onset blindness. Vision loss, which is irreversible,
      is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate,
      available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by
      35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate
      the potential benefits of oral Fenofibrate 145mg once daily for 12 months in 300 adults with
      Type 1 diabetes mellitus who are at high risk of eye damage.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central zone macular thickness measured using optical coherence tomography</measure>
    <time_frame>At 12 months after randomisation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total macular volume measured using optical coherence tomography.</measure>
    <time_frame>At 12 months after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuminuria measured as urinary albumin:creatinine ratio.</measure>
    <time_frame>Assessed at 12 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity using Snellen Chart</measure>
    <time_frame>At 12 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal confocal microscopic measurement of neural damage (only assessed in a representative subset of the participants at sites with the specialised confocal microscope).</measure>
    <time_frame>At 12 months after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate using MDRD formula</measure>
    <time_frame>At 12 months after randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy status assessed by temperature sensation and monofilament sensation.</measure>
    <time_frame>At 12 months after randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular function using non-invasive pulse wave techniques and plethysmography.</measure>
    <time_frame>At 12 months after randomisation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids and biomarkers in plasma</measure>
    <time_frame>At 6 weeks, 6 months and 12 months after randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Retinopathy</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Oral Fenofibrate 145mg given once daily for 12 months.</description>
    <arm_group_label>Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inert lactose placebo</intervention_name>
    <description>Oral matching inert lactose placebo given once daily for 12 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 1 diabetes mellitus

          -  Over 18 years of age

          -  Established macular thickening on optical coherence tomography (OCT) greater than or
             equal to 300 micrometres in at least one macular zone

          -  No definite indication for receiving, and no contraindication to receiving fenofibrate
             in addition to their existing therapy

        Exclusion Criteria:

          -  Subjects with type 1 diabetes mellitus and the contraindications of definite need for
             intra-ocular treatment or photocoagulation therapy within next 3 months

          -  Allergy to any fibrate drugs

          -  History of pancreatitis or pulmonary embolism or DVT

          -  Use of any other investigational agents in last 8 weeks

          -  Unstable condition including recent MI, heart failure, prior organ transplant, severe
             renal or liver dysfunction, history of myositis or untreated hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Keech, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sydney, NHMRC Clinical Trials Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Keech, Professor</last_name>
    <phone>+61 2 95625003</phone>
    <email>tony@ctc.usyd.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia Jenkins, Professor</last_name>
    <phone>+1 4052504069</phone>
    <email>alicia-jenkins@ouhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oklahoma University Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alicia Jenkins, Professor</last_name>
      <email>alicia-jenkins@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Alicia Jenkins, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Lyons, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHMRC Clinical Trials Centre</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Keech, Professor</last_name>
      <email>tony@ctc.usyd.edu.au</email>
    </contact>
    <investigator>
      <last_name>Anthony Keech, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Twigg, Professor</last_name>
      <email>stephen.twigg@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Twigg, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Children's Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Donaghue, Professor</last_name>
      <email>kimd@chw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Kim Donaghue, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Colman, Professor</last_name>
      <email>peter.colman@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter Colman, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>January 15, 2012</last_update_submitted>
  <last_update_submitted_qc>January 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Professor Anthony Keech</name_title>
    <organization>University of Sydney, NHMRC Clinical Trials Centre</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>Retinopathy</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

